Cardiology AdvisorNew ACC Scientific Statement Addresses Antiplatelet Therapy in ASCVD

📋 Guideline Update

The American College of Cardiology has released a 2026 scientific statement providing consensus recommendations on antiplatelet therapy across the ASCVD continuum, emphasizing individualized assessment of ischemic versus bleeding risk when selecting therapy for primary prevention, acute coronary syndrome, chronic coronary disease, peripheral artery disease, and patients requiring concomitant anticoagulation.

Clinical Considerations

• Low-dose aspirin for primary prevention may be considered in adults aged 40-70 years at elevated cardiovascular risk who do not have increased bleeding risk; routine use in adults older than 70 years is discouraged.
• For ACS patients undergoing PCI, prasugrel or ticagrelor remain the preferred P2Y12 inhibitors, though clopidogrel may be favored in some older patients because of bleeding concerns.
• De-escalation to clopidogrel approximately 1 month after ACS and PCI may be appropriate for select patients to reduce bleeding risk.
• Emerging evidence suggests clopidogrel monotherapy may offer similar ischemic protection with comparable or lower bleeding risk than aspirin for long-term secondary prevention following ACS.
• In selected high-risk patients with stable CAD or PAD, rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily may provide additional benefit when bleeding risk is acceptable.
• The statement advises minimizing or avoiding triple therapy when oral anticoagulation and antiplatelet therapy are both required.

Practice Applications

• Reassess aspirin use for primary prevention using contemporary risk-benefit frameworks rather than routine prescribing.
• Individualize DAPT duration and intensity based on both ischemic and bleeding risk profiles.
• Consider de-escalation strategies in appropriate post-PCI patients to improve safety and adherence.
• Evaluate long-term secondary prevention options, including potential roles for clopidogrel monotherapy and dual-pathway inhibition in carefully selected patients.
• Address adherence barriers through early follow-up, patient education, and strategies that reduce treatment complexity.